These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33480648)

  • 41. [Eculizumab as rescue therapy for lupus nephritis-related thrombotic microangiopathy].
    Fani FM; Patera A; Delsante M; Rossi GM; Manenti L; Landini S; Regolisti G; Fiaccadori E
    G Ital Nefrol; 2020 Jun; 37(3):. PubMed ID: 32530153
    [TBL] [Abstract][Full Text] [Related]  

  • 42. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
    Notaro R; Sica M
    Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy.
    Gabr JB; Bilal H; Mirchia K; Perl A
    J Investig Med High Impact Case Rep; 2020; 8():2324709620947266. PubMed ID: 32757799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria.
    Hill A; Richards SJ; Rother RP; Hillmen P
    Haematologica; 2007 Mar; 92(3):e31-3. PubMed ID: 17405753
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Etiopathological mechanisms and clinical characteristics of hyperhemolysis syndrome in Spanish patients with thalassemia.
    Vagace JM; Cardesa R; Corbacho A; Vázquez T; de la Maya MD; Gonzalez FA; Nieto JB; Urrutia E; Gómez MJ; Pascual T; Aguinaco MR; Gervasini G
    Ann Hematol; 2016 Sep; 95(9):1419-27. PubMed ID: 27392662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report.
    Abe T; Sasaki A; Ueda T; Miyakawa Y; Ochiai H
    Medicine (Baltimore); 2017 Feb; 96(6):e6056. PubMed ID: 28178155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early failure of eculizumab in a patient with malignant atrophic papulosis: Is it time for initial combination therapy of eculizumab and treprostinil?
    Razanamahery J; Payet-Revest C; Mareschal A; Saizonou I; Bonnet L; Gil H; Humbert S; Magy-Bertrand N
    J Dermatol; 2020 Jan; 47(1):e22-e23. PubMed ID: 31631389
    [No Abstract]   [Full Text] [Related]  

  • 49. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
    Fakhouri F; Fila M; Hummel A; Ribes D; Sellier-Leclerc AL; Ville S; Pouteil-Noble C; Coindre JP; Le Quintrec M; Rondeau E; Boyer O; Provôt F; Djeddi D; Hanf W; Delmas Y; Louillet F; Lahoche A; Favre G; Châtelet V; Launay EA; Presne C; Zaloszyc A; Caillard S; Bally S; Raimbourg Q; Tricot L; Mousson C; Le Thuaut A; Loirat C; Frémeaux-Bacchi V
    Blood; 2021 May; 137(18):2438-2449. PubMed ID: 33270832
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.
    Kello N; Khoury LE; Marder G; Furie R; Zapantis E; Horowitz DL
    Semin Arthritis Rheum; 2019 Aug; 49(1):74-83. PubMed ID: 30598332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy.
    Hisano M; Ashida A; Nakano E; Suehiro M; Yoshida Y; Matsumoto M; Miyata T; Fujimura Y; Hattori M
    Pediatr Int; 2015 Apr; 57(2):313-7. PubMed ID: 25868950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report.
    Alabdulqader M; Alfakeeh K
    BMC Nephrol; 2021 Apr; 22(1):140. PubMed ID: 33879077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
    Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R
    J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
    JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
    Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
    Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Horse anti-thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or no-go?
    Alashkar F; Dührsen U; Röth A
    Eur J Haematol; 2016 Oct; 97(4):403-5. PubMed ID: 26990688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion.
    Uhlmann EJ; Shenoy S; Goodnough LT
    Transfusion; 2014 Feb; 54(2):384-8. PubMed ID: 23692505
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tocilizumab in the management of posttransfusion hyperhemolysis syndrome in sickle cell disease: The experience so far.
    Meenan J; Hall R; Badle S; Chatterjee B; Win N; Tsitsikas DA
    Transfusion; 2022 Mar; 62(3):546-550. PubMed ID: 35092617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab.
    Servais A; Devillard N; Frémeaux-Bacchi V; Hummel A; Salomon L; Contin-Bordes C; Gomer H; Legendre C; Delmas Y
    Nephrol Dial Transplant; 2016 Dec; 31(12):2122-2130. PubMed ID: 27587606
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical characteristics of 512 eculizumab-naive paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study.
    Du Y; Yang Y; Yang C; Chen M; Han B
    Hematology; 2022 Dec; 27(1):113-121. PubMed ID: 35068377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.